Literature DB >> 10834617

Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire.

C Ferrand1, E Robinet, E Contassot, J M Certoux, A Lim, P Hervé, P Tiberghien.   

Abstract

We have initiated a phase I/II clinical trial, involving the use of herpes simplex thymidine kinase gene (HS-tk)-expressing donor primary T cells, in order to modulate the graft-versus-host disease (GvHD) occurring after allogeneic hematopoietic stem cell transplantation. The preparation of gene-modified T cells (TkTCs) required a 12-day ex vivo culture comprising an initial OKT3 and IL-2 stimulation, a retrovirus-mediated transduction, and a 7-day selection step in the presence of G418 and IL-2. The low transduction efficiency as well as the culture conditions may significantly alter the diversity of the T cell repertoire. We therefore examined the T cell repertoire of HS-tk-expressing T cell samples from 11 different donors by the Immunoscope method. This method analyzes the hypervariable region of the T cell receptor beta chain (TCRBV) by amplifying the complementarity-determining region 3 (CDR3) and determining size diversity. In all examined samples (four of which were infused into patients), all TCRBV subfamilies were represented with, however, a significant skewing within a minority of subfamilies. Kinetic studies demonstrated that this skewing appeared between day 7 and day 12, with dates of appearance variable from one subfamily to another. In addition, the repertoire analysis of two different culture products, harvested and produced at different times from the same donors, suggested that some repertoire abnormalities could be donor specific. Quantitative analysis revealed no major modifications in gene usage, even in skewed TCRBV subfamilies, with a few clonal expansions concerning a limited number of TCRBV subfamilies. Importantly, identical abnormalities were found in control cells grown in parallel under similar conditions but not transduced or selected, thus demonstrating that these abnormalities were not related to the transduction or the selection process, but rather to the ex vivo culture. The initial stimulus used for T cell activation is a major source of TCRBV perturbation, since replacing the OKT3 + IL-2 stimulus by CD3 + CD28 monoclonal antibody-coated beads prevented the occurrence of alterations. Overall, the HS-tk-expressing T cells used in our clinical trial exhibit limited TCR repertoire skewing that is not due to the transduction/selection procedure. However, future T cell gene transfer protocols for clinical trials should be designed to take into account or possibly prevent such T cell repertoire alterations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834617     DOI: 10.1089/10430340050015202

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  14 in total

1.  Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Elena Provasi; Anna Silvani; Marina Radrizzani; Claudia Benati; Elke Dammann; Annika Krons; Julia Kontsendorn; Joerg Schmidtke; Wolfgang Kuehnau; Nils von Neuhoff; Michael Stadler; Fabio Ciceri; Chiara Bonini; Arnold Ganser; Bernd Hertenstein; Eva M Weissinger
Journal:  Hum Gene Ther       Date:  2011-03-30       Impact factor: 5.695

Review 2.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

3.  Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system.

Authors:  Xin Huang; Andrew C Wilber; Lei Bao; Dong Tuong; Jakub Tolar; Paul J Orchard; Bruce L Levine; Carl H June; R Scott McIvor; Bruce R Blazar; Xianzheng Zhou
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

4.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Authors:  Carolina Berger; Mary E Flowers; Edus H Warren; Stanley R Riddell
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

5.  Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency.

Authors:  Ornellie Bernadin; Fouzia Amirache; Anais Girard-Gagnepain; Ranjita Devi Moirangthem; Camille Lévy; Kuiying Ma; Caroline Costa; Didier Nègre; Christian Reimann; David Fenard; Agata Cieslak; Vahid Asnafi; Hanem Sadek; Rana Mhaidly; Marina Cavazzana; Chantal Lagresle-Peyrou; François-Loïc Cosset; Isabelle André; Els Verhoeyen
Journal:  Blood Adv       Date:  2019-02-12

6.  B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

Authors:  Zhao-Yang Lu; Maud Condomines; Karin Tarte; Laure Nadal; Marie Claude Delteil; Jean François Rossi; Christophe Ferrand; Bernard Klein
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

7.  Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.

Authors:  Cyrille J Cohen; Zhili Zheng; Regina Bray; Yangbing Zhao; Linda A Sherman; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

8.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

9.  Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Authors:  Nicolas Montcuquet; Patricia Mercier-Letondal; Sylvain Perruche; Anne Duperrier; Mélanie Couturier; Abdelghani Bouchekioua; Mark Bonyhadi; Christophe Ferrand; Pierre Tiberghien; Eric Robinet
Journal:  Immunology       Date:  2008-04-26       Impact factor: 7.397

10.  Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Authors:  E Bôle-Richard; C Gamonet; J-M Certoux; I Idirene; F Larosa; E Deconinck; A-M Mosseley; P Tiberghien; C Borg; C Ferrand; M Deschamps
Journal:  Gene Ther       Date:  2016-05-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.